JP6924211B2 - 炎症を処置するための化合物および方法 - Google Patents

炎症を処置するための化合物および方法 Download PDF

Info

Publication number
JP6924211B2
JP6924211B2 JP2018557295A JP2018557295A JP6924211B2 JP 6924211 B2 JP6924211 B2 JP 6924211B2 JP 2018557295 A JP2018557295 A JP 2018557295A JP 2018557295 A JP2018557295 A JP 2018557295A JP 6924211 B2 JP6924211 B2 JP 6924211B2
Authority
JP
Japan
Prior art keywords
acid
chemerin
composition
lipid
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018557295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507182A (ja
JP2019507182A5 (enExample
Inventor
チャールズ コーエン，
チャールズ コーエン，
クリシュナ クマール，
クリシュナ クマール，
アラン エス． コピン，
アラン エス． コピン，
ベンジャミン エヌ． ハーウッド，
ベンジャミン エヌ． ハーウッド，
ベンカタ エス． ラマン，
ベンカタ エス． ラマン，
ペドラム ハムラー，
ペドラム ハムラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts Medical Center Inc
Tufts University
Original Assignee
Tufts Medical Center Inc
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts Medical Center Inc, Tufts University filed Critical Tufts Medical Center Inc
Publication of JP2019507182A publication Critical patent/JP2019507182A/ja
Publication of JP2019507182A5 publication Critical patent/JP2019507182A5/ja
Priority to JP2021125537A priority Critical patent/JP2021169531A/ja
Application granted granted Critical
Publication of JP6924211B2 publication Critical patent/JP6924211B2/ja
Priority to JP2023029552A priority patent/JP7432028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2018557295A 2016-01-22 2017-01-23 炎症を処置するための化合物および方法 Active JP6924211B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021125537A JP2021169531A (ja) 2016-01-22 2021-07-30 炎症を処置するための化合物および方法
JP2023029552A JP7432028B2 (ja) 2016-01-22 2023-02-28 炎症を処置するための化合物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662286070P 2016-01-22 2016-01-22
US62/286,070 2016-01-22
PCT/US2017/014605 WO2017127827A1 (en) 2016-01-22 2017-01-23 Compounds and methods for treating inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021125537A Division JP2021169531A (ja) 2016-01-22 2021-07-30 炎症を処置するための化合物および方法

Publications (3)

Publication Number Publication Date
JP2019507182A JP2019507182A (ja) 2019-03-14
JP2019507182A5 JP2019507182A5 (enExample) 2020-03-05
JP6924211B2 true JP6924211B2 (ja) 2021-08-25

Family

ID=57963487

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018557295A Active JP6924211B2 (ja) 2016-01-22 2017-01-23 炎症を処置するための化合物および方法
JP2021125537A Pending JP2021169531A (ja) 2016-01-22 2021-07-30 炎症を処置するための化合物および方法
JP2023029552A Active JP7432028B2 (ja) 2016-01-22 2023-02-28 炎症を処置するための化合物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021125537A Pending JP2021169531A (ja) 2016-01-22 2021-07-30 炎症を処置するための化合物および方法
JP2023029552A Active JP7432028B2 (ja) 2016-01-22 2023-02-28 炎症を処置するための化合物および方法

Country Status (7)

Country Link
US (3) US11197906B2 (enExample)
EP (1) EP3405208B1 (enExample)
JP (3) JP6924211B2 (enExample)
AU (1) AU2017210118B2 (enExample)
CA (1) CA3012190A1 (enExample)
ES (1) ES2805037T3 (enExample)
WO (1) WO2017127827A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10233219B2 (en) 2013-04-12 2019-03-19 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
WO2017127827A1 (en) 2016-01-22 2017-07-27 Tufts Medical Center Compounds and methods for treating inflammation
JP7251036B2 (ja) * 2018-06-28 2023-04-04 ポーラ化成工業株式会社 皮膚老化改善剤のスクリーニング方法
WO2021021915A1 (en) * 2019-08-01 2021-02-04 Okyo Pharma Limited Compositions comprising chemerin analogs and methods of use
WO2023220676A2 (en) * 2022-05-12 2023-11-16 Okyo Pharma Limited Formulation for treating dry eye disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US5200473A (en) 1988-03-25 1993-04-06 Jeanneret Gris Gilbert Chelating resins and method for their use in the extraction of metal ions
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6365156B1 (en) 1999-04-16 2002-04-02 Osel, Inc. Method for improving the half-life of soluble viral-specific ligands on mucosal membranes
IL160142A0 (en) 2001-08-17 2004-06-20 Anosys Inc Methods and compounds for the targeting of protein to exosomes
US7169892B2 (en) 2003-01-10 2007-01-30 Astellas Pharma Inc. Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems
US20060263336A1 (en) 2003-03-24 2006-11-23 Caplan Arnold I Cell targeting methods and compositions
WO2005121755A1 (en) 2004-06-14 2005-12-22 Commonwealth Scientific And Industrial Research Organisation Cell free g-protein coupled receptor and ligand assay
CN101947310A (zh) 2004-10-27 2011-01-19 丹佛大学 促肾上腺皮质激素类似物以及相关方法
CA2611365C (en) 2005-06-14 2014-02-11 Cellzome Ag Process for the identification of novel enzyme interacting compounds
US8242058B2 (en) 2006-07-21 2012-08-14 Wisconsin Alumni Research Foundation Reagents and methods for appending functional groups to proteins
JP2010229093A (ja) 2009-03-27 2010-10-14 Banyu Pharmaceut Co Ltd 新規ＣｈｅｍｅｒｉｎＲアゴニスト
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
US20120245229A1 (en) 2009-09-15 2012-09-27 Ru-Rong Ji Method for treating neuropathic pain
EP2533764A4 (en) 2010-02-08 2016-08-31 Univ Nebraska BIOMINERAL AND METAL BINDING LIPOSOME, THEIR SYNTHESIS AND METHOD FOR THE PRODUCTION THEREOF
US8883177B2 (en) 2011-06-28 2014-11-11 Nian Wu Pharmaceutical compositions for parenteral administration
EP2766032A4 (en) * 2011-10-13 2015-04-29 Thomas Gadek TOPICAL FORMULATIONS OF PEPTIDES CHÉMÉRINE C15 FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
US10233219B2 (en) 2013-04-12 2019-03-19 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
WO2017127827A1 (en) 2016-01-22 2017-07-27 Tufts Medical Center Compounds and methods for treating inflammation

Also Published As

Publication number Publication date
US12053501B2 (en) 2024-08-06
JP2019507182A (ja) 2019-03-14
US11197906B2 (en) 2021-12-14
AU2017210118B2 (en) 2023-05-04
JP2023059999A (ja) 2023-04-27
EP3405208A1 (en) 2018-11-28
AU2017210118A1 (en) 2018-08-09
JP2021169531A (ja) 2021-10-28
CA3012190A1 (en) 2017-07-27
WO2017127827A1 (en) 2017-07-27
US20240325486A1 (en) 2024-10-03
EP3405208B1 (en) 2020-04-29
ES2805037T3 (es) 2021-02-10
US20220054581A1 (en) 2022-02-24
JP7432028B2 (ja) 2024-02-15
US20190022168A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
JP7432028B2 (ja) 炎症を処置するための化合物および方法
ES2644016T3 (es) Péptidos para su uso en el tratamiento tópico de enfermedades neurodegenerativas retinianas, en particular en estadios tempranos de retinopatía diabética y otras enfermedades retinianas en las que la neurodegeneración desempeña un papel esencial
KR20110110174A (ko) 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
US20210315890A1 (en) Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
JP2015536344A (ja) 外胚葉異形成症の治療のための組成物及び方法
JP7651553B2 (ja) ケメリン類似体を含む組成物とその使用方法
HK40000831B (en) Compounds and methods for treating inflammation
HK40000831A (en) Compounds and methods for treating inflammation
EP4007636B1 (en) Compositions comprising bovine adrenal medulla 8-22 (bam8-22) peptide analogs and methods of use
EP4522118A2 (en) Chemerin-containing formulation for treating dry eye disease
CN106794225A (zh) 肉豆蔻酰化的瘦素相关肽及其用途
HK40075089B (en) Compositions comprising chemerin analogs and methods of use
HK40075089A (en) Compositions comprising chemerin analogs and methods of use
BR112015020143B1 (pt) Composição tópica farmacêutica no tratamento ocular tópico e/ou na prevenção de doenças neurodegenerativas da retina

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210730

R150 Certificate of patent or registration of utility model

Ref document number: 6924211

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250